AAPS NBC 2026 signals that predictive tools are moving to center stage in drug discovery
The opening plenary at AAPS NBC 2026 is set to spotlight predictive tools, underscoring how much the field has shifted toward computational decision support. That focus suggests drug discovery is increasingly about anticipating failures earlier, not just generating more candidates.
Conference programming often reflects where a field believes its next source of leverage lies, and the emphasis on predictive tools is telling. In drug discovery, better prediction can improve everything from formulation choices to candidate selection and development planning. The fact that this is being elevated at a major meeting suggests the discipline now sees predictive analytics as central rather than peripheral.
This is part of a larger realignment in pharma. For years, discovery teams have generated more data than they could effectively use. Predictive tools are attractive because they promise to turn that data into decision advantage, reducing wasted experiments and helping teams focus on the most promising paths.
But predictive power is only valuable if it is trusted and embedded in real workflows. Many teams have adopted advanced modeling tools only to find that scientists still default to familiar heuristics when the stakes rise. The real challenge is therefore not just technical performance, but cultural and operational integration.
The AAPS plenary matters because it indicates the field is treating prediction as a core capability rather than a niche specialty. That is a meaningful signal that AI in drug discovery is becoming institutionalized, with conferences, workflows, and decision processes adapting around it.